Terms ending in 2030
Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,883,803 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors Grace period ended Nov 11, 2026 · lapse expected · Low confidence | Pharmacyclics LLC | Grace period ended Nov 11, 2026 lapse expected | Low confidence | |
| US 8,466,193 | Selective Inhibitors of Histone Deacetylase In force · High confidence | Pharmacyclics LLC | In force | High confidence | |
| US 9,403,032 | Formulations of Histone Deacetylase Inhibitor and Uses Therof In force · Medium confidence | Pharmacyclics LLC | In force | Medium confidence | |
| US 8,552,046 | Manufacture, Compositions and Uses of Coagulation Factor Viia Modulator In force · High confidence | Pharmacyclics LLC | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.